The short answer: a structured assessment, not one fixed bundle
If you are asking which tests are needed before Mounjaro or Wegovy, the accurate answer is not one list that requires every person to have the same blood panel and scan. Before prescribing obesity medication, a structured assessment starts with weight history, related diseases, current medicines, blood pressure and examination. The clinician then selects investigations that could actually change the decision. The 2026 obesity standards describe useful evaluation elements but explicitly state that the list should not be interpreted as universally required. NICE takes the same approach: record baseline measures and select investigations according to the history and examination [1, 2, 3].
Assessment commonly considers A1C or another suitable glucose measure, kidney function, liver enzymes and platelets, and a lipid profile. Thyroid tests, a complete blood count, iron studies, vitamin B12, vitamin D and pregnancy testing are selected according to symptoms, history and the proposed plan, not simply because the medicine is tirzepatide or semaglutide [1, 3]. Abdominal ultrasound can be useful when there is biliary pain, a gallstone history, abnormal liver tests, suspected fatty liver or a kidney question. It is not listed in current medication labels as a routine prerequisite for every person [4, 5, 6].
Every investigation should answer a question. Is there unrecognized diabetes? Would dehydration carry extra risk because of kidney disease? Does suspected liver disease need staging? Do upper-abdominal symptoms justify gallbladder imaging? Our guide to who can take weight-loss injections covers eligibility and formal contraindications; this article focuses on preparing for a safe assessment without unnecessary testing or unsafe shortcuts [1, 2, 3].
Before tests: history and medicines can change the plan
A pre-treatment visit is more than ordering a laboratory sheet. Tell the clinician about current diagnoses, previous experiences with weight or diabetes medicines, and every prescribed medicine and supplement. Insulin and sulfonylureas can increase hypoglycemia risk when combined with GLP-1 or dual GIP/GLP-1 medicines, so glucose results and the diabetes regimen need review before treatment and during follow-up. Do not reduce insulin or stop a diabetes medicine yourself; adjustment belongs with the clinician managing diabetes [4, 5, 6].
Report any personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), because current labels list them as contraindications. Also discuss previous pancreatitis, biliary pain or gallstones, repeated vomiting, severe gastroparesis or prolonged fullness after small meals, medicine allergy, and any current or previous eating disorder. Comprehensive obesity evaluation also considers sleep, eating pattern, mental health, drivers of weight gain and previous treatments, because medicine selection cannot rest on the scale alone [1, 2, 4, 5].
Pregnancy possibility or plans need discussion before prescribing a weight-loss medicine. Current labels warn against weight-reduction use during pregnancy and include medicine-specific advice about planned pregnancy and oral contraception with tirzepatide. This article cannot set an individual stopping date or contraception plan; the prescriber should review the relevant label and circumstances before treatment [4, 5, 6]. Ordinary hypothyroidism or Hashimoto's disease is not the same as MTC or MEN2, and an incidental silent gallstone does not automatically prohibit treatment. The exact diagnosis determines the next step [4, 5, 6].
Possible baseline tests: each one answers a question
Hemoglobin A1C reflects average glucose over recent months, while fasting plasma glucose is a measurement at one point in time. Either may identify diabetes or prediabetes and inform treatment selection. Glucose review becomes especially important for someone using insulin or a sulfonylurea because combined treatment can increase hypoglycemia risk. A1C does not require fasting; fasting plasma glucose requires at least an eight-hour fast according to test instructions [4, 5, 7]. Anemia and conditions that alter red-cell survival can make A1C less representative, so the clinician interprets it alongside glucose and context [7]. Our HbA1c test guide explains the result and its limits in more detail.
Kidney function, including creatinine and estimated filtration rate, records a baseline and may identify a condition that makes dehydration more consequential. The labels call for renal monitoring when vomiting, diarrhea or another adverse effect could cause volume depletion, particularly during initiation and escalation. This does not mean the medicine damages every person's kidneys; it means significant dehydration should not be ignored [4, 5]. Liver enzymes and platelets may expose a problem needing assessment and contribute to noninvasive liver-fibrosis calculations. An abnormal result is not a diagnosis by itself, and ordinary ultrasound may show liver fat but cannot determine inflammation or fibrosis alone [1, 10].
A lipid panel assesses cardiovascular risk and includes triglycerides. Very high blood lipid levels can contribute to pancreatitis, but this does not make pancreatic enzymes or pancreatic imaging routine screening tests for everyone starting an injection [9, 12]. TSH is useful when symptoms suggest hypothyroidism or another clinical reason exists; the 2026 standards present it as an indicated test, not an automatic prerequisite for every prescription [1]. The aim is not to collect the largest possible number of results. It is to find information that will change treatment or the safety plan.
CBC, iron, B12 and vitamin D: when do they add information?
A complete blood count may be appropriate for persistent fatigue, pallor, bleeding, heavy menstrual loss, an anemia history or a restricted diet. Iron and ferritin, vitamin B12 and vitamin D are not supplements that every injection user automatically needs. Obesity evaluation standards place vitamin and mineral status among tests selected when indicated. NICE similarly lists full blood count, thyroid, kidney and liver testing as examples directed by the history and examination [1, 3].
The reason is practical. An injection may reduce appetite and food intake, but that alone does not diagnose a particular deficiency. Appropriate testing together with a food and symptom review separates a true deficiency from unnecessary supplementation and helps select food, supplementation and follow-up if a deficiency is confirmed. There is no universal vitamin dose attached to the name Mounjaro or Wegovy, and excessive supplementation without an indication is not a substitute for balanced nutrition or medical monitoring [1, 2].
Pregnancy testing is selected when pregnancy is possible and the result would change the treatment plan. This should be discussed respectfully and without assumptions. Current weight-management medicine labels make pregnancy relevant to the use decision, so testing or timing review may matter before treatment and later according to circumstances [1, 4, 5]. Pancreatic enzymes such as lipase and amylase are not listed as routine tests for every asymptomatic person in the evaluations cited here. Severe, persistent upper-abdominal pain, particularly when it radiates to the back or occurs with vomiting, requires urgent assessment when it happens rather than reassurance from an old test [4, 5, 9].
Ultrasound before weight-loss injections: useful selectively, not routine for all
Abdominal ultrasound is a safe test without ionizing radiation and can assess the liver, gallbladder, bile ducts, kidneys and visible portions of the pancreas. It still needs a defined clinical question. For right-upper-abdominal pain, a previous gallstone or suspected gallbladder disease, ultrasound is the standard first imaging test for finding gallstones. Semaglutide and tirzepatide labels describe gallbladder events and call for gallbladder studies and follow-up when disease is suspected, not mandatory screening ultrasound for every asymptomatic person [4, 5, 8]. Read what abdominal ultrasound can show for its preparation and limitations, and our gallstones guide when symptoms need assessment.
Ultrasound can show an appearance compatible with fatty liver, which can help when the history, examination or blood tests make that question relevant. Ordinary ultrasound cannot determine steatohepatitis or stage fibrosis on its own. The next step may involve liver enzymes, platelets, a risk score or specialist imaging rather than repeated ordinary scans [1, 10]. Kidney imaging can show anatomy, some stones or obstruction, but it does not replace creatinine and estimated filtration rate when assessing kidney function [1, 11].
Pancreatic visibility may be limited by bowel gas and tissue depth. A reassuring-looking image therefore cannot exclude pancreatitis, and routine abdominal ultrasound is not a pancreatic eligibility test before an injection. Assessment uses symptoms, examination, laboratory results and appropriate imaging when pancreatitis is suspected [9, 11]. Thyroid ultrasound is not a routine response to the boxed warning either. The labels state that routine calcitonin monitoring or thyroid ultrasound has uncertain value for early MTC detection. A nodule found on examination or imaging follows its own evaluation pathway [4, 5, 6].
Do pre-treatment tests require fasting? It depends on the test
Do not fast automatically just because you are attending a pre-injection assessment. A1C does not require fasting. Fasting plasma glucose usually requires at least eight hours without food or caloric drinks, with water permitted according to the testing service's instructions [7]. A laboratory may ask for fasting before a lipid panel, particularly when triglycerides are central to the question, so follow the actual request rather than assuming [12]. Kidney tests, liver tests, TSH, blood counts and vitamin tests do not all share one fasting rule, and a clinician may combine several tests under instructions chosen for the group.
Do not stop a regular medicine on the morning of testing without advice. Ask specifically about diabetes medicines, insulin, thyroid medicine and supplements because fasting while using some diabetes treatments may require a plan to avoid hypoglycemia. Drink water if the instructions permit; dehydration can make blood collection harder and affect some results. When abdominal or gallbladder ultrasound is requested, the imaging service may ask you not to eat for a period to improve gallbladder views. Preparation varies with the requested area, and urgent imaging for severe symptoms should not be delayed merely to complete routine preparation [8, 11].
Ask for written instructions covering fasting duration, water, medicines and appointment time. Tell the team before fasting if you have diabetes, pregnancy, or become dizzy while fasting. A useful result is not only an accurate number; it is a test completed safely at a time that answers the clinical question. Bring recent results from a reliable laboratory rather than automatically repeating them. NICE permits previous assessments to be used when they remain appropriate and recent enough [3].
If a test or scan finds something, what might change?
An abnormal result does not automatically prohibit an injection, but it should not be ignored. High glucose may turn a weight-only visit into a complete diabetes plan, including review of insulin or sulfonylurea to reduce hypoglycemia risk. Reduced kidney function may change the fluid and laboratory monitoring plan, especially if vomiting or diarrhea develops. Abnormal liver enzymes or platelets, or liver fat seen on ultrasound, may lead to fibrosis risk calculation or further assessment rather than treating ultrasound as the end of diagnosis [1, 4, 5, 10].
An incidental silent gallstone differs from recurrent biliary pain or cholecystitis. The clinician connects imaging with symptoms and examination, then may investigate or treat the problem before starting or set a clear symptom plan. Very high triglycerides or a history of pancreatitis requires review of the underlying risk and careful treatment selection; it should not become an automatic internet decision either to start or refuse treatment [5, 9]. MTC or MEN2 history is different because it is a formal contraindication, while hypothyroidism usually needs appropriate control and follow-up rather than an automatic ban. Our Mounjaro, Wegovy and thyroid guide explains that distinction [4, 5, 6].
During treatment, monitoring follows need: weight, blood pressure, symptoms, food and fluid intake and diabetes medicines, followed by targeted tests. Labels call for glucose monitoring in people with diabetes and kidney-function monitoring when symptoms may cause volume depletion. NICE recommends regular reviews during escalation to discuss effectiveness, adverse effects and nutrition [3, 4, 5]. There is no universal timetable for repeating every vitamin test and ultrasound every month. Severe persistent abdominal pain, vomiting that prevents fluid intake, markedly reduced urination, jaundice, or right-upper-abdominal pain with fever requires prompt assessment rather than waiting for a routine review [4, 5, 8, 9].
Next step: prepare for medical review before the injection decision
Before the appointment, prepare a medicine and supplement list, photographs of any previous injection boxes or pens, recent laboratory or ultrasound reports, and a clear weight and symptom history. Record previous biliary pain, pancreatitis or severe vomiting, and identify diabetes medicines that can cause hypoglycemia. The aim is for the clinician to determine what is already known, what is missing and what will not help, instead of ordering duplicated investigations [1, 2, 3].
At La Rose, internal-medicine consultation with ultrasound is available at the Maadi branch with Dr Mohab Ashraf on Saturday. Weight-management follow-up can then continue with the medical team at La Rose. Having ultrasound available within the assessment pathway does not mean everyone must have it; the decision follows the history, examination and clinical question [3, 11]. You can book an internal-medicine and ultrasound assessment before deciding on a weight-loss injection and bring your results and current medicines.
Do not start an injection from an unknown source, and do not change a diabetes, thyroid or blood-pressure medicine yourself because of one result. Seek urgent assessment for severe persistent abdominal pain that may radiate to the back, repeated vomiting that prevents fluid intake, markedly reduced urination, jaundice, or fever with right-upper-abdominal pain. Pre-treatment assessment aims for a safer choice and an understandable monitoring plan. It cannot guarantee that a medicine is suitable or that normal baseline results remove every risk [4, 5, 8, 9].
